Loading…
Oramed Pharmaceuticals Inc. is projected to rise to $4.94 by 2027, a +20% move from its current price of $4.12. ORMP is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $4.00 | $4.12 | $4.25 | +0.01% |
| Jul 13 | $3.94 | $4.12 | $4.31 | +0.03% |
| Jul 14 | $3.91 | $4.12 | $4.35 | +0.04% |
| Jul 15 | $3.87 | $4.12 | $4.39 | +0.05% |
| Jul 16 | $3.85 | $4.12 | $4.42 | +0.06% |
| Jul 17 | $3.82 | $4.12 | $4.45 | +0.08% |
| Jul 18 | $3.80 | $4.12 | $4.48 | +0.09% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.80 | $4.12 | $4.48 | +0.09% |
| Week 2 | $3.68 | $4.13 | $4.63 | +0.18% |
| Week 3 | $3.59 | $4.13 | $4.76 | +0.27% |
| Week 4 | $3.51 | $4.13 | $4.87 | +0.36% |
| Week 5 | $3.45 | $4.14 | $4.97 | +0.45% |
| Week 6 | $3.39 | $4.14 | $5.06 | +0.54% |
| Week 7 | $3.34 | $4.15 | $5.15 | +0.63% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes.
The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
Oramed Pharmaceuticals Inc. (ORMP) currently trades at $4.30 per share and sits with a market cap of $175.98M. It is ranked 3915 by market capitalization. The stock’s near-term outlook is shaped by a forecast that foresees continued upside through multiple years, with the 2026–2035 period showing a rising average price and bullish sentiment after an initial neutral stance in 2026-2027.
Looking further out, the model’s average forecast climbs from $4.30 in 2026 to a $9.45 average by 2030 and ultimately to $44.51 by 2050, with corresponding ROIs of 119.8% (2030) and 935.2% (2050). The forecast also notes persistent bullish sentiment from 2028 onward, punctuated by strong upside in the 2033–2050 window.
A major floor 31.7% below — a decisive break under it would weaken the trend.
The nearest floor, 12.6% below — buyers have tended to step in here.
The nearest ceiling, 21.4% above — a clean break opens room to run.
A major ceiling 36.2% above — clearing it would confirm fresh momentum.
Key ORMP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ORMP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.28 | Sell | $4.24 | Sell |
| MA 10 | $4.47 | Sell | $4.32 | Sell |
| MA 20 | $4.26 | Sell | $4.27 | Sell |
| MA 50 | $4.13 | Sell | $4.10 | Buy |
| MA 100 | $3.83 | Buy | $3.86 | Buy |
| MA 200 | $3.32 | Buy | $3.46 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.53 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -44.93 | Neutral |
| Williams %R (14) | -96.97 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -3.12 | Sell |
| Bollinger %B (20,2) | 0.35 | Neutral |
| Stochastic %K (14) | 3.03 | Buy |
| TRIX (15) | 0.46 | Buy |
| Awesome (5,34) | 0.18 | Buy |
| Ultimate (7,14,28) | 22.51 | Buy |
| Momentum (10) | -0.96 | Sell |
| Aroon Osc (25) | 48.00 | Buy |
| Hull MA (9) | 4.07 | Buy |
| ADX (14) | 16.54 | Neutral |
| ATR (14) | 0.13 | Info |
The 30-day technical picture is bullish. RSI(14) is 50, and the moving averages show momentum above a stable base: SMA(50) at $4.12 and SMA(200) at $3.30. Near-term support is identified at $3.60 and resistance at $5.00, suggesting a defined trading range with upside potential beyond the upper bound.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.91 | $4.12 | $5.61 | 0% | Neutral | |
| $3.89 | $4.94 | $6.68 | +20% | Neutral | |
| $5.04 | $6.62 | $9.32 | +61% | Bullish | |
| $5.81 | $7.83 | $11.39 | +90% | Bullish | |
| $6.67 | $9.20 | $13.75 | +123% | Bullish | |
| $6.92 | $9.77 | $14.94 | +137% | Bullish | |
| $6.51 | $9.37 | $14.62 | +127% | Bullish | |
| $7.62 | $11.19 | $17.80 | +172% | Bullish | |
| $8.70 | $13.00 | $21.05 | +216% | Bullish | |
| $9.85 | $14.98 | $24.65 | +264% | Bullish | |
| $12.41 | $20.42 | $35.93 | +396% | Bullish | |
| $24.01 | $45.39 | $88.05 | +10.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.91 | $4.12 | $5.00 | +0.00% |
| August 2026 | $3.47 | $4.11 | $5.01 | -0.26% |
| September 2026 | $3.49 | $4.17 | $5.15 | +1.45% |
| October 2026 | $3.68 | $4.43 | $5.52 | +6.21% |
| November 2026 | $3.73 | $4.51 | $5.67 | +1.75% |
| December 2026 | $3.64 | $4.42 | $5.61 | -1.81% |
Click any year to see its month-by-month ORMP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect ORMP to range from $2.91 to $5.61 through 2026. The $4.12 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The ORMP price prediction for 2027 points to an average of $4.94 (low $3.89, high $6.68) — a potential gain of +20% on today's $4.12. Price action looks broadly range-bound.
In 2028, ORMP is projected to trade between $5.04 and $9.32, averaging $6.62 — a potential gain of +61% from today's $4.12. That is up +34% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Oramed Pharmaceuticals Inc.'s 2029 outlook centres on $7.83, within a $5.81 to $11.39 range. That is up +18% on the projected 2028 average. That marks a +90% change versus current levels. Momentum favours further upside here.
By 2030, ORMP could reach as high as $13.75, with a base case around $9.20 and support toward $6.67 — roughly +123% from $4.12. Buyers look set to stay in control over this stretch.
Expect ORMP to range from $6.92 to $14.94 through 2031. The $9.77 average target implies a +137% move from current prices. That is up +6% on the projected 2030 average. Momentum favours further upside here.
The ORMP price prediction for 2032 points to an average of $9.37 (low $6.51, high $14.62) — a potential gain of +127% on today's $4.12. Buyers look set to stay in control over this stretch.
In 2033, ORMP is projected to trade between $7.62 and $17.80, averaging $11.19 — a potential gain of +172% from today's $4.12. That is up +19% on the projected 2032 average. Momentum favours further upside here.
Oramed Pharmaceuticals Inc.'s 2034 outlook centres on $13.00, within a $8.70 to $21.05 range. That is up +16% on the projected 2033 average. That marks a +216% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, ORMP could reach as high as $24.65, with a base case around $14.98 and support toward $9.85 — roughly +264% from $4.12. Momentum favours further upside here.
Expect ORMP to range from $12.41 to $35.93 through 2040. The $20.42 average target implies a +396% move from current prices. That is up +36% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The ORMP price prediction for 2050 points to an average of $45.39 (low $24.01, high $88.05) — a potential gain of +10.0x on today's $4.12. Momentum favours further upside here.
Investing $1,000 in ORMP today (≈ 242.718447 ORMP) could be worth
$11,018.18
+$10,018.18 (+1002%) by 2050 · US Dollar
Based on the average projected ORMP price of $45.39 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ORMPwould be worth at today's price.
$1,000 invested in ORMP on Jul 10, 2025 (≈ 471.698139 ORMP) would be worth
$1,943.4
+$943.4 (+94.3%) today · 1.94× · US Dollar
Based on a ORMP entry price of $2.12 vs. today's $4.12.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.6 | $895.65 | -10.4% |
| 1 month ago | $3.7 | $1,113.51 | +11.4% |
| 3 months ago | $3.53 | $1,167.14 | +16.7% |
| 6 months ago | $3.43 | $1,201.17 | +20.1% |
| 1 year ago | $2.12 | $1,943.4 | +94.3% |
| All time (5.0y) ago | $13.6 | $302.94 | -69.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ORMP forecast.
Our base-case forecast reaches $8.20 around 2030.
Implied market cap at $8.20: $335.59M
The multi-year forecast indicates a sustained bullish trajectory, with 2026 labeled Neutral and subsequent years from 2028 onward labeled Bullish. The 2030 average price is $9.45 with a 119.8% ROI, followed by continued upside such as 2040 average $20.02 and 365.5% ROI, and 2050 average $44.51 with 935.2% ROI. The 2033–2035 period shows higher medians ($11.28, $12.98, $14.96) as part of the extended bullish arc toward 2050.
The forecast also provides a wide potential range for each year, with 2040’s min $11.89, max $35.85 and 2050’s min $22.75, max $88.14. While these figures illustrate substantial upside, they are estimates and not guarantees, and outcomes depend on market conditions and clinical development progress. The asset exhibits notable volatility historically, and investors should consider the associated risks as part of any longer-term view.
Tap a question to reveal the answer.
2030 forecast: min $6.77, avg $9.45, max $14.28, ROI 119.8%, sentiment BULLISH.
Forecasts show a bullish trajectory with 2030 avg $9.45 and 2050 avg $44.51, ROI up to 119.8% (2030) and 935.2% (2050). These are estimates, not guarantees, and depend on factors such as market conditions and clinical progress.
Yes. The forecast includes a 2026 max of $5.86 and a 2027 max of $6.94, indicating near-term upside beyond current levels (with the 30-day range high at $5.33).
Current price is $4.30 and market cap is $175.98M; the rank is 3915.
The near-term technical picture is BULLISH. RSI(14) is 50; SMA(50) is $4.12; SMA(200) is $3.30. Support is at $3.60 and resistance at $5.00, with a 30-day range of $3.47–$5.33 and annualized volatility of 60%.
Oramed Pharmaceuticals Inc. Community Discussion
0Share your Oramed Pharmaceuticals Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.